Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive with news the Australian Patent Office has granted Canntab an Australian Patent related to its proprietary cannabidiol formulations.
Goldstein talks about another validation of their technology with this patent and also the fact they have a purchase order from Australia. Goldstein also told Proactive the company will be taking part in Australia's Largest Observational Medical Cannabis Research Study ever.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE